Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

Next Previous
X
Search
Trial Profile

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions
  • Sponsors Aldeyra Therapeutics

    • Most Recent Events

    • 24 Feb 2020 According to an Aldeyra Therapeutics media release, the company will present combined data analyses from this and Part 1 of ReNew trial.
    • 24 Feb 2020 Results presented in an Aldeyra Therapeutics media release.
    • 09 May 2019 According to an Aldeyra Therapeutics media release, results from this study were presented at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top